Gout flares among adults in the United States are significantly underreported to healthcare providers, with nearly 72% of flares either not reported or pretreated/prevented by patients, according to ...

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating ...

XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

The following is a summary of “Improving Gout Care in a Canadian Academic Medical Center Through a Multidisciplinary ...